A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs HTERT DNA vaccine Invectys (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Invectys
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 Results (n=20) of clinical and pharmacodynamic assessment of INVAC-1 as a single agent in patients with refractory/progressive advanced solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 01 Mar 2017 Planned number of patients changed from 18 to 26.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History